Elena Bartoloni

List of Publications by Citations

160 papers	3,223 citations	34 h-index	53 g-index
175 ext. papers	4,002 ext. citations	4.7 avg, IF	5.07 L-index

#	Paper	IF	Citations
160	Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. *Mediators of Inflammation*, **2015**, 2015, 751793	4.3	178
159	EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. *RMD Open*, **2015**, 1, e000022	5.9	150
158	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). *Annals of the Rheumatic Diseases*, **2016**, 75, 382-9	2.4	144
157	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). *Annals of the Rheumatic Diseases*, **2015**, 74, 859-66	2.4	138
156	Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. *Rheumatology*, **2014**, 53, 839-44	3.9	129
155	Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. *Clinical and Developmental Immunology*, **2012**, 2012, 823085		108
154	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study. *Medicine (United States)*, **2015**, 94, e1144	1.8	91
153	COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. *Immunologic Research*, **2020**, 68, 213-224	4.3	90
152	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. *Journal of Autoimmunity*, **2020** , 111, 102468	15.5	76
151	IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. *Annals of the Rheumatic Diseases*, **2013**, 72, 286-92	2.4	73
150	Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. *Journal of Internal Medicine*, **2015**, 278, 185-92	10.8	71
149	Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. *Arthritis Care and Research*, **2011**, 63, 178-83	4.7	71
148	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. *Frontiers in Pharmacology*, **2017**, 8, 369	5.6	68
147	Diagnosis and classification of autoimmune hypophysitis. *Autoimmunity Reviews*, **2014**, 13, 412-6	13.6	62
146	Cardiac involvement in systemic rheumatic diseases: An update. *Autoimmunity Reviews*, **2010**, 9, 849-52	13.6	58
145	Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. *Autoimmunity Reviews*, **2015**, 14, 1019-22	13.6	56
144	A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. *Lupus*, **2015**, 24, 315-20	2.6	55

143	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren?s syndrome? Association between clinical, histopathological, and molecular features: a retrospective study. *Seminars in Arthritis and Rheumatism*, **2014**, 44, 314-24	5.3	54
142	CD4(-)CD8(-) T-cells in primary Sjögren's syndrome: association with the extent of glandular involvement. *Journal of Autoimmunity*, **2014**, 51, 38-43	15.5	53
141	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. *Clinical and Experimental Rheumatology*, **2015**, 33, 449-56	2.2	51
140	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. *Clinical Reviews in Allergy and Immunology*, **2017**, 52, 71-80	12.3	48
139	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. *Journal of Clinical Medicine*, **2019**, 8,	5.1	48
138	Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome. *Rheumatology*, **2013**, 52, 1387-96	3.9	46
137	Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. *Arthritis Research and Therapy*, **2013**, 15, R16	5.7	44
136	T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. *Mediators of Inflammation*, **2015**, 2015, 243723	4.3	44
135	Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. *Autoimmunity Reviews*, **2012**, 11, 815-20	13.6	41
134	Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjögren's syndrome. *Lupus*, **2011**, 20, 928-35	2.6	40
133	Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. *Scandinavian Journal of Rheumatology*, **2015**, 44, 36-41	1.9	38
132	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. *Autoimmunity Reviews* , **2017**, 16, 253-257	13.6	37
131	In vitro immunomodulatory effects of microencapsulated umbilical cord Wharton jelly-derived mesenchymal stem cells in primary Sjögren's syndrome. *Rheumatology*, **2015**, 54, 163-8	3.9	37
130	How early is the atherosclerotic risk in rheumatoid arthritis?. *Autoimmunity Reviews*, **2010**, 9, 701-7	13.6	37
129	Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients. *Arthritis Research and Therapy*, **2014**, 16, 444	5.7	35
128	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). *Clinical and Experimental Rheumatology*, **2018** , 36 Suppl 112, 102-112	2.2	34
127	Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. *Nature Reviews Cardiology*, **2018**, 15, 33-44	14.8	33
126	Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjögren's syndrome: new markers of chronic endothelial damage?. *Rheumatology*, **2015**, 54, 536-44	3.9	29

125	Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: a new era for therapeutic targeting?. *Autoimmunity Reviews*, **2014**, 13, 1167-73	13.6	29
124	Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study. *Clinical and Experimental Immunology*, **2016**, 184, 284-92	6.2	28
123	Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatment. *Annals of the Rheumatic Diseases*, **2012**, 71, 1151-6	2.4	27
122	One year in review 2015: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2015**, 33, 259-71	2.2	27
121	Cardiovascular disease in systemic sclerosis. *Annals of Translational Medicine*, **2015**, 3, 8	3.2	26
120	Myositis in primary Sjögren's syndrome: data from a multicentre cohort. *Clinical and Experimental Rheumatology*, **2015**, 33, 457-64	2.2	26
119	Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. *Clinical and Experimental Rheumatology*, **2020**, 38, 754-759	2.2	26
118	Extra-articular rheumatoid arthritis. *Reumatismo*, **2018**, 70, 212-224	1.1	25
117	Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. *Journal of Rheumatology*, **2017**, 44, 1179-1183	4.1	24
116	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. *Arthritis and Rheumatology*, **2020**, 72, 1314-1324	9.5	24
115	Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. *Expert Opinion on Biological Therapy*, **2015**, 15, 1727-37	5.4	24
114	Outcome of pregnancy in Italian patients with primary Sjögren syndrome. *Journal of Rheumatology*, **2013**, 40, 1143-7	4.1	22
113	Interferon gamma-inducible protein 16 in primary Sjögren's syndrome: a novel player in disease pathogenesis?. *Arthritis Research and Therapy*, **2015**, 17, 208	5.7	20
112	One year in review 2016: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2016**, 34, 161-71	2.2	20
111	Rituximab in primary Sjögren's syndrome: a ten-year journey. *Lupus*, **2014**, 23, 1337-49	2.6	19
110	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. *Frontiers in Pharmacology*, **2019**, 10, 296	5.6	17
109	Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy. *Clinical Reviews in Allergy and Immunology*, **2013**, 44, 14-22	12.3	17
108	Plant-Derived Chimeric Virus Particles for the Diagnosis of Primary Sjögren Syndrome. *Frontiers in Plant Science*, **2015**, 6, 1080	6.2	16

107	Serum interleukin-17 in primary Sjögren's syndrome: association with disease duration and parotid gland swelling. *Clinical and Experimental Rheumatology*, **2015**, 33, 129	2.2	15
106	Platelets Contribute to the Accumulation of Matrix Metalloproteinase Type 2 in Synovial Fluid in Osteoarthritis. *Thrombosis and Haemostasis*, **2017**, 117, 2116-2124	7	14
105	Insulin-Like Growth Factor Binding Protein 6 in Rheumatoid Arthritis: A Possible Novel Chemotactic Factor?. *Frontiers in Immunology*, **2017**, 8, 554	8.4	14
104	Circulating Interferon-Inducible Protein IFI16 Correlates With Clinical and Serological Features in Rheumatoid Arthritis. *Arthritis Care and Research*, **2016**, 68, 440-5	4.7	14
103	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. *Autoimmunity Reviews*, **2021**, 20, 102738	13.6	14
102	Role of regulatory T cells in rheumatoid arthritis: facts and hypothesis. *Autoimmunity Highlights*, **2010**, 1, 45-51	3.7	13
101	One year in review 2019: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 118, 3-15	2.2	13
100	Central Hemodynamics and Arterial Stiffness in Systemic Sclerosis. *Hypertension*, **2016**, 68, 1504-1511	8.5	12
99	Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. *Expert Review of Cardiovascular Therapy*, **2010**, 8, 1309-16	2.5	11
98	Prevention and treatment of autoimmune diseases with plant virus nanoparticles. *Science Advances* , **2020**, 6, eaaz0295	14.3	10
97	One year in review 2018: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 112, 14-26	2.2	10
96	One year in review 2020: comorbidities, diagnosis and treatment of primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 10-22	2.2	10
95	Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. *Journal of Clinical Medicine*, **2019**, 8,	5.1	9
94	The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients. *PLoS ONE*, **2013**, 8, e53336	3.7	9
93	Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?. *Frontiers in Cardiovascular Medicine*, **2018**, 5, 177	5.4	9
92	Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands. *PLoS ONE*, **2019**, 14, e0211142	3.7	8
91	Ultrasound revealing subclinical enthesopathy at the greater trochanter level in patients with spondyloarthritis. *Clinical Rheumatology*, **2012**, 31, 463-8	3.9	8
90	The dark side of Sjögren's syndrome: the possible pathogenic role of infections. *Current Opinion in Rheumatology*, **2019**, 31, 505-511	5.3	8

89	Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections. *Microorganisms*, **2021**, 9,	4.9	8
88	Role of Inflammatory Diseases in Hypertension. *High Blood Pressure and Cardiovascular Prevention*, **2017**, 24, 353-361	2.9	7
87	The kaleidoscope of neurological manifestations in primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 118, 192-198	2.2	7
86	Subclinical Atherosclerosis in Primary Sjögren's Syndrome: Does Inflammation Matter?. *Frontiers in Immunology*, **2019**, 10, 817	8.4	6
85	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. *Frontiers in Medicine*, **2020**, 7, 42	4.9	6
84	The classification criteria for Sjögren syndrome: issues for their improvement from the study of a large Italian cohort of patients. *Annals of the Rheumatic Diseases*, **2014**, 73, e35	2.4	6
83	The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans. *Annals of the Rheumatic Diseases*, **2014**, 73, e42	2.4	6
82	The clinical spectrum of primary Sjögren's syndrome: beyond exocrine glands. *Reumatismo*, **2017**, 69, 93-100	1.1	6
81	Beneficial cardiovascular effects of low-dose glucocorticoid therapy in inflammatory rheumatic diseases. *Journal of Rheumatology*, **2012**, 39, 1758-60; author reply 1761	4.1	6
80	The prevalence and relevance of traditional cardiovascular risk factors in primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 112, 113-120	2.2	6
79	The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart. *Clinical and Experimental Rheumatology*, **2020**, 38, 580	2.2	6
78	Interferon gamma-inducible protein 16 (IFI16) and anti-IFI16 antibodies in primary Sjögren's syndrome: findings in serum and minor salivary glands. *Reumatismo*, **2015**, 67, 85-90	1.1	5
77	Drugs in induction and treatment of idiopathic inflammatory myopathies. *Autoimmunity Highlights*, **2014**, 5, 95-100	3.7	5
76	The Impact of SARS-CoV-2 Outbreak on Primary Sjögren's Syndrome: An Italian Experience. *Frontiers in Medicine*, **2020**, 7, 608728	4.9	4
75	Association Between Glandular Infiltrate and Leukopenia in Sjögren Syndrome (SS): Data From the Italian Research Group on SS (GRISS). *Journal of Rheumatology*, **2020**, 47, 1840-1841	4.1	4
74	Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future. *Frontiers in Pharmacology*, **2021**, 12, 635663	5.6	4
73	The onset site of rheumatoid arthritis: the joints or the lung?. *Reumatismo*, **2016**, 68, 167-175	1.1	4
72	Effect of Sinovial High-Low injections in trapeziometacarpal osteoarthritis. *Clinical and Experimental Rheumatology*, **2019**, 37, 166	2.2	4

71	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 118, 97-106	2.2	4
70	The use of digital image analysis in the histological assessment of Sjögren's syndrome salivary glands improves inter-rater agreement and facilitates multicentre data harmonisation. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 180-188	2.2	4
69	Hypertension and SARS-CoV-2 infection: is inflammation the missing link?. *Cardiovascular Research*, **2020**, 116, e193-e194	9.9	3
68	The Need to Target Mucosa-Associated Lymphoid Tissue for Preventing Lymphoma in Rheumatoid Factor-Positive Patients With Sjögren's Syndrome: Comment on the Article by Nocturne et al. *Arthritis and Rheumatology*, **2016**, 68, 1318-9	9.5	3
67	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. *Journal of Autoimmunity*, **2021**, 124, 102729	15.5	3
66	Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2017**, 35, 546-547	2.2	3
65	One year in review 2021: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2021**,	2.2	3
64	Novel insights on lymphoma and lymphomagenesis in primary Sjögren's Syndrome. *Panminerva Medica*, **2020**,	2	2
63	Clinical Features **2016**, 11-33		2
62	Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 112, 73-79	2.2	2
61	Novel Therapeutic Strategies in Primary Sjögren's Syndrome. *Israel Medical Association Journal*, **2017**, 19, 576-580	0.9	2
60	Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2018**, 36 Suppl 112, 210-214	2.2	2
59	One year in review 2021: Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2021**, 39, 3-13	2.2	2
58	COVID-19: the new challenge for rheumatologists. One year later. *Clinical and Experimental Rheumatology*, **2021**, 39, 203-213	2.2	2
57	Anticyclic Citrullinated Peptide Antibodies in Patients with Rheumatic Diseases other than Rheumatoid Arthritis: Clinical or Pathogenic Significance?. *Journal of Rheumatology*, **2015**, 42, 1063-4	4.1	1
56	THU0194 Role of Platelets in the Pathogenesis of Osteoarthritis and Biological Effects of Hyaluronic Acid: in Vivo and in Vitro Study. *Annals of the Rheumatic Diseases*, **2014**, 73, 248.3-249	2.4	1
55	Images in clinical medicine: Unusual bursal fluid. *New England Journal of Medicine*, **2013**, 369, 1945	59.2	1
54	SAT0398 Diagnostic value of anti mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: A multicentric study by firma group. *Annals of the Rheumatic Diseases*, **2013**, 71, 607.1-607	2.4	1

53	Unattended compared to traditional blood pressure measurement in patients with rheumatoid arthritis: a randomised cross-over study. *Annals of Medicine*, **2021**, 53, 2050-2059	1.5	1
52	Identification of a Novel Serological Marker in Seronegative Rheumatoid Arthritis Using the Peptide Library Approach. *Frontiers in Immunology*, **2021**, 12, 753400	8.4	1
51	Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome. *Journal of Internal Medicine*, **2020**, 287, 214-215	10.8	1
50	Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M . The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. *Annals of the Rheumatic Diseases*, **2020**,	2.4	1
49	Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. *Frontiers in Immunology*, **2021**, 12, 615656	8.4	1
48	Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary Sjögren's syndrome: a novel pathogenetic scenario?. *Clinical and Experimental Rheumatology*, **2019**, 37 Suppl 118, 133-139	2.2	1
47	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 85-94	2.2	1
46	COVID-19: the new challenge for rheumatologists. One year later. *Clinical and Experimental Rheumatology*, **2021**, 39, 203-213	2.2	1
45	Adherence to the Mediterranean diet and the impact on clinical features in primary Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2021**, 39, 190-196	2.2	1
44	THU0341 Correlation between Essdai and Clinessdai in A Real-Life Cohort of Sjögren's Syndrome Patients. *Annals of the Rheumatic Diseases*, **2016**, 75, 310.2-310	2.4	0
43	FRI0024 Interferon Gamma-Inducible Protein 16 (IFI16) in Rheumatoid Arthritis: A Novel Biomarker for Pulmonary Involvement?. *Annals of the Rheumatic Diseases*, **2015**, 74, 427.1-427	2.4	0
42	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations.. *Clinical Reviews in Allergy and Immunology*, **2022**, 1	12.3	0
41	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts.. *Computational and Structural Biotechnology Journal*, **2022**, 20, 471-484	6.8	0
40	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. *Clinical Reviews in Allergy and Immunology*, **2021**, 1	12.3	0
39	Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology. *Lupus*, **2021**, 30, 1233-1243	2.6	0
38	A Platelet's Guide to Synovitis. *Israel Medical Association Journal*, **2019**, 21, 454-459	0.9	0
37	Development and Implementation of the AIDA International Registry for Patients With Still's Disease.. *Frontiers in Medicine*, **2022**, 9, 878797	4.9	0
36	Traditional and disease-related non-computed variables affect algorithms for cardiovascular risk estimation in Sjögren's syndrome and rheumatoid arthritis. *Clinical and Experimental Rheumatology*, **2021**, 39, 107-113	2.2	0

35	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. *Clinical and Experimental Rheumatology*, **2021**, 39, 166-174	2.2	0
34	Relevance of Interferon-Inducible Protein-16 Rather than Anti-Interferon-Inducible Protein-16 Autoantibodies as a Clinical and Pathogenic Biomarker in Primary Sjögren's Syndrome: Comment on the Article by Baer et al. *Arthritis Care and Research*, **2017**, 69, 453-454	4.7	
33	Th17 Cells **2019**, 37-44		
32	A8.6 A novel therapeutic approach in systemic rheumatic autoimmune disorders: encapsulated human umbilical cord wharton jelly-derived mesenchymal stem cells. *Annals of the Rheumatic Diseases*, **2015**, 74, A83.2-A83	2.4	
31	SAT0030 Circulating Endothelial Microparticles and Endothelial Progenitors Cells in Primary Sjögren's Syndrome: New Markers of Chronic Endothelial Damage?. *Annals of the Rheumatic Diseases*, **2014**, 73, 599.3-600	2.4	
30	FRI0180 Correlation Between Clinimetric Approach and German US7 Score in Rheumatoid Arthritis Patients Treated with Tocilizumab: A Pilot Study. *Annals of the Rheumatic Diseases*, **2015**, 74, 489.1-489	2.4	
29	THU0393 IL-17 Producing Pathogenic T Lymphocytes Co-Express CD20 and are Depleted by Rituximab in Primary sjögren's Syndrome: A Novel Target for an Old Weapon. *Annals of the Rheumatic Diseases*, **2015**, 74, 339.1-339	2.4	
28	AB0564 Disease Damage is Associated with Increased Aortic Stiffness in Systemic Lupus Erythematosus: A Cross-Sectional Study. *Annals of the Rheumatic Diseases*, **2015**, 74, 1088.3-1088	2.4	
27	SAT0377 Interferon Gamma-Inducible Protein 16 (IFI16) in Primary Sjögren's Syndrome: A Novel Player in Disease Pathogenesis?. *Annals of the Rheumatic Diseases*, **2015**, 74, 795.4-796	2.4	
26	SAT0212 Pregnancy and fetal outcome in patients with an established diagnosis of primary sjögren syndrome. *Annals of the Rheumatic Diseases*, **2013**, 71, 543.3-544	2.4	
25	A3.1 Pathogenic role of IL-17 producing double negative (DN) T cells in primary sjögren syndrome. *Annals of the Rheumatic Diseases*, **2014**, 73, A42.1-A42	2.4	
24	A3.8 Association between clinical, histopathological and molecular features in primary Sjögren Syndrome: a retrospective study. *Annals of the Rheumatic Diseases*, **2014**, 73, A45.1-A45	2.4	
23	AB0037 CD4+CD25-GITR+regulatory T cells are expanded in the blood, display suppressive function and are inversely correlated with disease activity in patients with primary Sjögren syndrome. *Annals of the Rheumatic Diseases*, **2013**, 71, 639.12-639	2.4	
22	FRI0282 Serological biomarkers of b-cell lymphoproliferative disorders in patients with primary sjögren syndrome: retrospective study in a large italian cohort. *Annals of the Rheumatic Diseases*, **2013**, 72, A469.3-A470	2.4	
21	SAT0219 Prevalence and predictive role of traditional cardiovascular risk factors in a cohort of sjögren syndrome patients. *Annals of the Rheumatic Diseases*, **2013**, 71, 546.1-546	2.4	
20	FRI0001 IL-17 producing-DN T cells are expanded in the blood, infiltrate salivary glands and are resistant to corticosteroids in sjögren syndrome. *Annals of the Rheumatic Diseases*, **2013**, 71, 311.1-311	2.4	
19	THU0192 Myositis in primary sjögren syndrome: Data from a multicenter cohort. *Annals of the Rheumatic Diseases*, **2013**, 71, 220.2-220	2.4	
18	THU0129 Selective elimination of pathogenic TH17 cells from peripheral blood of rheumatoid arthritis patients by a purified fungal polysaccharide. *Annals of the Rheumatic Diseases*, **2013**, 71, 198.3-198	2.4	

17	AB0952 Intra-articular low molecular weight hyaluronate reduces platelet influx and matrix metalloproteinase-2 levels in synovial fluid of patients with knee osteoarthritis. *Annals of the Rheumatic Diseases*, **2013**, 71, 693.3-693	2.4
16	THU0174 Endothelial microparticles and circulating endothelial progenitor cells in primary sjögren's syndrome patients: A potential marker of endothelial damage?. *Annals of the Rheumatic Diseases*, **2013**, 71, 214.2-214	2.4
15	SAT0187 Immunomodulatory effects of human umbilical cord wharton jelly-derived mesenchymal stem cells (HUCMS) on circulating T-cell subsets in patients with sjögren's syndrome. *Annals of the Rheumatic Diseases*, **2013**, 71, 534.3-535	2.4
14	A3.4 CD3+CD4−CD8− Double Negative Th17 Cells: New Insights in the Pathogenesis of Primary Sjögren's Syndrome. *Annals of the Rheumatic Diseases*, **2013**, 72, A14.2-A15	2.4
13	SAT0290 A Higher Disease Activity in Anti-Ssa/ssb Positive Sjögren's Syndrome Is Explained by A Higher Clinical and Biological B-Cell Activation. *Annals of the Rheumatic Diseases*, **2016**, 75, 773.2-773	2.4
12	T Cells in the Pathogenesis of Sjögren's Syndrome **2016**, 205-215	
11	AB0592 Evaluation of Arterial Stiffness in A Cohort of Systemic Sclerosis Patients: A Case-Control Study. *Annals of the Rheumatic Diseases*, **2016**, 75, 1107.1-1107	2.4
10	Comment on: Equal rights in autoimmunity: is Sjögren's syndrome ever 'secondary'?. *Rheumatology*, **2021**, 60, e32-e33	3.9
9	Different clinical presentations of primary Sjögren's syndrome: Not only a matter of age. Comment on: "Elderly-onset primary Sjögren's syndrome focused on clinical and salivary gland ultrasonographic features by Lee et al. Joint Bone Spine. 2021;88:105132". *Joint Bone Spine*, **2021**, 88, 105191	2.9
8	Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'. *Annals of the Rheumatic Diseases*, **2021**,	2.4
7	Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study. *Clinical and Experimental Rheumatology*, **2015**, 33, 445	2.2
6	Characterisation of articular manifestations in primary Sjögren's syndrome: clinical and imaging features. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 166-173	2.2
5	Significance of anti-La/SSB antibodies in primary Sjögren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 53-56	2.2
4	A Training Tool to support the management and diagnosis of Sjögren's syndrome. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 174-179	2.2
3	Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 189-194	2.2
2	Retinal detachment as the first manifestation of systemic lupus erythematosus. *Clinical and Experimental Rheumatology*, **2021**, 39, 924	2.2
1	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 133, 166-174	2.2